Oridonin in combination with imatinib exerts synergetic anti-leukemia effects in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway

Cancer Biology and Therapy

Volumn 13, Issue 13, 2012, Pages 1244-1254

  Guo, Yong ^a   Shan, Qingqing ^a   Gong, Yuping ^a   Lin, Juan ^a   Yang, Xi ^a   Zhou, Ruiqing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Akt mTOR; Anti leukemia effect; Imatinib; LYN; Oridonin; Philadelphia chromosome positive acute lymphoblastic leukemia; RAF MEK ERK; STAT5

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; ORIDONIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; RAF PROTEIN; STAT5 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZAMIDES; CELL PROLIFERATION; CELL SURVIVAL; DITERPENES, KAURANE; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE SIGNALING SYSTEM; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; RAF KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT5 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84868348363     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21460     Document Type: Article

References (49)

1. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001; 61:2343-55; PMID:11289094.
2. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138:819-30; PMID:12755554.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-30; PMID:2406902; http://dx.doi.org/10.1126/science.2406902.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-82; PMID:2408149; http://dx.doi.org/10.1126/science.2408149.
5. Cobaleda C, Gutiérrez-Cianca N, Pérez-Losada J, Flores T, García-Sanz R, González M, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95:1007-13; PMID:10648416.
6. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98:1337-54; PMID:14508819; http://dx.doi.org/10.1002/cncr.11664.
7. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15:21-36; PMID:11258387; http://dx.doi.org/10. 1016/S0889-8588(05)70198-2.
8. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, et al.; Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002; 100:2357-66;PMID: 12239143; http://dx.doi.org/10.1182/blood-2002-03-0704.
9. Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005; 130:489-500; PMID:16098062; http://dx.doi.org/10. 1111/j.1365-2141.2005.05611.x.
10. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001; 20:5826-35; PMID:11593388; http://dx.doi.org/10.1038/sj.onc. 1204549.
11. Jin A, Kurosu T, Tsuji K, Mizuchi D, Arai A, Fujita H, et al. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis and adhesion. Oncogene 2006; 25:4332-40; PMID:16518411; http://dx.doi.org/10.1038/sj.onc.1209459.
12. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ ABL and is required for leukemogenesis. J Exp Med 1999; 189:1229-42; PMID:10209040; http://dx.doi.org/10.1084/jem.189.8.1229.
13. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16:6151-61; PMID:9321394; http://dx.doi.org/10.1093/emboj/16.20.6151.
14. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-53; PMID:15618470; http://dx.doi.org/10.1182/blood-2004-08-3097.
15. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7; PMID:11287972; http://dx.doi.org/10.1056/NEJM200104053441401.
16. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17; PMID:17151364; http://dx.doi.org/10.1056/NEJMoa062867.
17. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6; PMID:8616716; http://dx.doi.org/10.1038/nm0596-561.
18. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al.; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004; PMID:12637609; http://dx.doi.org/10.1056/NEJMoa022457.
19. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36:453-61; PMID:15098032; http://dx.doi.org/10.1038/ng1343.
20. + leukemia in mice. Proc Natl Acad Sci U S A 2006; 103:16870-5; PMID:17077147; http://dx.doi.org/10.1073/pnas.0606509103.
21. Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010; 24:813-20; PMID:20111071; http://dx.doi.org/10.1038/ leu.2009.302.
22. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309-15; PMID:17496201; http://dx.doi.org/10.1182/blood-2007-02- 073528.
23. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27:469-71; PMID:19075254; http://dx.doi.org/10.1200/JCO.2008.19.8853.
24. Zhang JX, Han QB, Zhao AH, Sun HD. Diterpenoids from Isodon japonica. Fitoterapia 2003; 74:435-8; PMID:12837357; http://dx.doi.org/10.1016/S0367- 326X(03)00107-2.
25. Fujita E, Nagao Y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia 1976; 32:203-6; PMID:1269612; http://dx.doi.org/10.1007/BF01937766.
26. Fujita T, Takeda Y, Sun HD, Minami Y, Marunaka T, Takeda S, et al. Cytotoxic and antitumor activities of Rabdosia diterpenoids. Planta Med 1988; 54:414-7; PMID:3200934; http://dx.doi.org/10.1055/s-2006-962485.
27. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 2009; 490:70-5; PMID:19699177; http://dx.doi.org/10.1016/j. abb.2009.08.011.
28. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. Biol Pharm Bull 2007; 30:254-60; PMID:17268061; http://dx.doi.org/ 10.1248/bpb.30.254.
29. Li XT, Lin C, Li PY, Zhang TM. [Comparative study on the sensitivities of seven human cancer cell lines to rubescensine A]. Yao Xue Xue Bao 1985; 20:243-6; PMID:4072693.
30. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol 2005; 26:579-88; PMID:15703811.
31. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H, Koeffler HP. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 2003; 23:1187-93; PMID:12964003.
32. Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S, Ikejima T. Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci 2004; 96:155-63; PMID:15492467; http://dx.doi.org/10.1254/jphs.FPJ04008X.
33. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007; 109:3441-50; PMID:17197433; http://dx.doi.org/10. 1182/blood-2006-06-032250.
34. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41:93-141; PMID:2692037.
35. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10; PMID:12001991; http://dx.doi.org/10.1038/nrc780.
36. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22:686-707; PMID:18337767; http://dx.doi.org/10.1038/leu.2008.26.
37. Talapatra S, Thompson CB. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 2001; 298:873-8; PMID:11504779.
38. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009; 145:569-80; PMID:19344392; http://dx.doi.org/10.1111/j.1365-2141.2009.07657.x.
39. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108:2358-65; PMID:16763210; http://dx.doi.org/10.1182/blood-2006-02-003475.
40. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2010; 2:98-110; PMID:20201032; http://dx.doi.org/10.1002/emmm.201000062.
41. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21:5766-74; PMID:12411494; http://dx.doi.org/10.1093/emboj/cdf562.
42. Meyn MA 3rd, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281:30907-16; PMID:16912036; http://dx.doi.org/10.1074/jbc.M605902200.
43. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 1997; 10:223-31; PMID:9376661; http://dx.doi.org/10.1016/S0950-3536(97)80004-2.
44. Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther 2007; 6:261-8; PMID:17218775; http://dx.doi.org/10.4161/cbt.6.2.3621.
45. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. J Pharmacol Sci 2007; 103:56-66; PMID:17251686; http://dx.doi.org/10.1254/jphs. FPJ06016X.
46. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-42; PMID:11287973; http://dx.doi.org/10.1056/NEJM200104053441402.
47. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011; 117:3409-20; PMID:21220747; http://dx.doi.org/10.1182/blood-2009-10-248211.
48. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller- Brüsselbach S, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005; 19:1774-82; PMID:16136169; http://dx.doi.org/10.1038/sj.leu.2403898.
49. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004; 103:3167-74; PMID:15070699; http://dx.doi.org/10.1182/blood- 2003-04-1271.